August 2026 in “PLoS ONE” This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.
April 2026 in “The Breast” This study found that both scalp cooling systems and chemical cooling caps effectively reduced chemotherapy-induced alopecia in early breast cancer patients, with scalp cooling showing better early efficacy but chemical cooling providing greater psychological and quality of life benefits.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
19 citations
,
June 2018 in “Breast Cancer Research and Treatment” This study found that adjuvant docetaxel treatment for breast cancer at cumulative doses of 400 mg/m² or higher is associated with a 10% prevalence of persistent alopecia leading to wig use, but this was completely prevented with scalp cooling.
7 citations
,
January 2013 in “European Urology” This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.
